Literature DB >> 21135106

The disintegrin-like and cysteine-rich domains of ADAM-9 mediate interactions between melanoma cells and fibroblasts.

Paola Zigrino1, Roswitha Nischt, Cornelia Mauch.   

Abstract

A characteristic of malignant cells is their capacity to invade their surrounding and to metastasize to distant organs. During these processes, proteolytic activities of tumor and stromal cells modify the extracellular matrix to produce a microenvironment suitable for their growth and migration. In recent years the family of ADAM proteases has been ascribed important roles in these processes. ADAM-9 is expressed in human melanoma at the tumor-stroma border where direct or indirect interactions between tumor cells and fibroblasts occur. To analyze the role of ADAM-9 for the interaction between melanoma cells and stromal fibroblasts, we produced the recombinant disintegrin-like and cysteine-rich domain of ADAM-9 (DC-9). Melanoma cells and human fibroblasts adhered to immobilized DC-9 in a Mn(2+)-dependent fashion suggesting an integrin-mediated process. Inhibition studies showed that adhesion of fibroblasts was mediated by several β1 integrin receptors independent of the RGD and ECD recognition motif. Furthermore, interaction of fibroblasts and high invasive melanoma cells with soluble recombinant DC-9 resulted in enhanced expression of MMP-1 and MMP-2. Silencing of ADAM-9 in melanoma cells significantly reduced cell adhesion to fibroblasts. Ablation of ADAM-9 in fibroblasts almost completely abolished these cellular interactions and melanoma cell invasion in vitro. In summary, these results suggest that ADAM-9 expression plays an important role in mediating cell-cell contacts between fibroblasts and melanoma cells and that these interactions contribute to proteolytic activities required during invasion of melanoma cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135106      PMCID: PMC3057808          DOI: 10.1074/jbc.M110.168617

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Accelerated wound repair in ADAM-9 knockout animals.

Authors:  Cornelia Mauch; Jan Zamek; Anna N Abety; Gundula Grimberg; Jay W Fox; Paola Zigrino
Journal:  J Invest Dermatol       Date:  2010-04-08       Impact factor: 8.551

Review 2.  Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing.

Authors:  Coert Margadant; Arnoud Sonnenberg
Journal:  EMBO Rep       Date:  2010-01-15       Impact factor: 8.807

3.  A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis.

Authors:  Soledad R Alonso; Lorraine Tracey; Pablo Ortiz; Beatriz Pérez-Gómez; José Palacios; Marina Pollán; Juan Linares; Salvio Serrano; Ana I Sáez-Castillo; Lydia Sánchez; Raquel Pajares; Abel Sánchez-Aguilera; Maria J Artiga; Miguel A Piris; José L Rodríguez-Peralto
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

Review 4.  ADAM9 as a potential target molecule in cancer.

Authors:  Lucie Peduto
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

5.  Stromal expression of MMP-13 is required for melanoma invasion and metastasis.

Authors:  Paola Zigrino; Isolde Kuhn; Tobias Bäuerle; Jan Zamek; Jay W Fox; Susanne Neumann; Alexander Licht; Marina Schorpp-Kistner; Peter Angel; Cornelia Mauch
Journal:  J Invest Dermatol       Date:  2009-06-11       Impact factor: 8.551

6.  Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer.

Authors:  Christina H Stuelten; Johanna I Busch; Binwu Tang; Kathleen C Flanders; Akira Oshima; Emily Sutton; Tatiana S Karpova; Anita B Roberts; Lalage M Wakefield; John E Niederhuber
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

7.  ADAM9 is involved in pathological retinal neovascularization.

Authors:  Victor Guaiquil; Steven Swendeman; Tsunehiko Yoshida; Sai Chavala; Peter A Campochiaro; Carl P Blobel
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

8.  ADAM-15/metargidin mediates homotypic aggregation of human T lymphocytes and heterotypic interactions of T lymphocytes with intestinal epithelial cells.

Authors:  Laetitia Charrier; Yutao Yan; Hang Thi Thu Nguyen; Guillaume Dalmasso; Christian L Laboisse; Andrew T Gewirtz; Shanthi V Sitaraman; Didier Merlin
Journal:  J Biol Chem       Date:  2007-04-06       Impact factor: 5.157

9.  Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor.

Authors:  Oliver M Fischer; Stefan Hart; Andreas Gschwind; Norbert Prenzel; Axel Ullrich
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 10.  The ADAM metalloproteinases.

Authors:  Dylan R Edwards; Madeleine M Handsley; Caroline J Pennington
Journal:  Mol Aspects Med       Date:  2008-08-15
View more
  22 in total

1.  Sorting nexin 9 (SNX9) regulates levels of the transmembrane ADAM9 at the cell surface.

Authors:  Kasper J Mygind; Theresa Störiko; Marie L Freiberg; Jacob Samsøe-Petersen; Jeanette Schwarz; Olav M Andersen; Marie Kveiborg
Journal:  J Biol Chem       Date:  2018-04-05       Impact factor: 5.157

2.  ADAM9 is a novel product of polymorphonuclear neutrophils: regulation of expression and contributions to extracellular matrix protein degradation during acute lung injury.

Authors:  Robin Roychaudhuri; Anja H Hergrueter; Francesca Polverino; Maria E Laucho-Contreras; Kushagra Gupta; Niels Borregaard; Caroline A Owen
Journal:  J Immunol       Date:  2014-07-25       Impact factor: 5.422

3.  ADAM8 localizes to extravillous trophoblasts within the maternal-fetal interface and potentiates trophoblast cell line migration through a β1 integrin-mediated mechanism.

Authors:  H T Le; J Atif; D L Mara; B Castellana; J Treissman; J Baltayeva; A G Beristain
Journal:  Mol Hum Reprod       Date:  2018-10-01       Impact factor: 4.025

4.  Deletion of ADAM-9 in HGF/CDK4 mice impairs melanoma development and metastasis.

Authors:  N Giebeler; A Schönefuß; J Landsberg; T Tüting; C Mauch; P Zigrino
Journal:  Oncogene       Date:  2017-05-29       Impact factor: 9.867

Review 5.  The pleiotropic roles of ADAM9 in the biology of solid tumors.

Authors:  Victor O Oria; Paul Lopatta; Oliver Schilling
Journal:  Cell Mol Life Sci       Date:  2018-03-17       Impact factor: 9.261

6.  Platelet integrin α6β1 controls lung metastasis through direct binding to cancer cell-derived ADAM9.

Authors:  Elmina Mammadova-Bach; Paola Zigrino; Camille Brucker; Catherine Bourdon; Monique Freund; Adèle De Arcangelis; Scott I Abrams; Gertaud Orend; Christian Gachet; Pierre Henri Mangin
Journal:  JCI Insight       Date:  2016-09-08

7.  Senescent fibroblasts in melanoma initiation and progression: an integrated theoretical, experimental, and clinical approach.

Authors:  Eunjung Kim; Vito Rebecca; Inna V Fedorenko; Jane L Messina; Rahel Mathew; Silvya S Maria-Engler; David Basanta; Keiran S M Smalley; Alexander R A Anderson
Journal:  Cancer Res       Date:  2013-09-30       Impact factor: 12.701

8.  A Disintegrin and A Metalloproteinase-9 (ADAM9): A Novel Proteinase Culprit with Multifarious Contributions to COPD.

Authors:  Xiaoyun Wang; Francesca Polverino; Joselyn Rojas-Quintero; Duo Zhang; José Sánchez; Ilyas Yambayev; Eva Lindqvist; Robert Virtala; Ratko Djukanovic; Donna E Davies; Susan Wilson; Rory O'Donnell; Danen Cunoosamy; Petra Hazon; Andrew Higham; Dave Singh; Henric Olsson; Caroline A Owen
Journal:  Am J Respir Crit Care Med       Date:  2018-06-04       Impact factor: 21.405

9.  Angiotensin converting enzyme (ACE) and ACE2 bind integrins and ACE2 regulates integrin signalling.

Authors:  Nicola E Clarke; Martin J Fisher; Karen E Porter; Daniel W Lambert; Anthony J Turner
Journal:  PLoS One       Date:  2012-04-16       Impact factor: 3.240

Review 10.  Influence of Tumor Microenvironment and Fibroblast Population Plasticity on Melanoma Growth, Therapy Resistance and Immunoescape.

Authors:  Veronica Romano; Immacolata Belviso; Alessandro Venuta; Maria Rosaria Ruocco; Stefania Masone; Federica Aliotta; Giuseppe Fiume; Stefania Montagnani; Angelica Avagliano; Alessandro Arcucci
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.